Prelude Therapeutics Inc (PRLD): Nasdaq/NYSE listing notice — Prelude Therapeutics receives Nasdaq bid price deficiency notice; has until Sep 23, 2025 to cure

Prelude Therapeutics Inc

Nasdaq notified Prelude on March 27, 2025 that its common stock closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until September 23, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.
If not compliant by Sep 23, Prelude may qualify for a second 180-day period if it meets other standards and intends a reverse stock split.
No immediate impact on listing; stock continues trading on Nasdaq under symbol PRLD.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Prelude Therapeutics Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 27, 2025, Prelude Therapeutics Inc (the “Company”) received a letter (the “Bid Price Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Bi

View on SEC.gov

Browse all listing & compliance notices →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-25-046839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.